Skip to main content

Table 2 Effect of IT baclofen and a GABAB receptor antagonist on responses to urinary bladder distension in rats with and without previous episode of bladder inflammation as neonates and/or as adults (data presented as % baseline AUC)

From: Systemic and intrathecal baclofen produce bladder antinociception in rats

Pretreatments NBI No NBI No NBI
Plus ABI Plus ABI No ABI
SEQUENCE 1    
Saline IT 145.8 ± 24.0 110.1 ± 5.7 132.1 ± 15.9
Then 40 ng IT baclofen 46.1 ± 10.9* 63.5 ± 12.8* 64.7 ± 17.3*
SEQUENCE 2    
CGP35348 IT (30 mcg) 104.1 ± 12.7 101.2 ± 6.0 138.5 ± 25.0
Then 40 ng IT baclofen 90.7 ± 11.3# 102.1 ± 5.7# 134.8 ± 28.5#
SEQUENCE 3    
CGP35348 IT (30 mcg) 106.2 ± 13.8 130.7 ± 12.7 123.8 ± 13.5
Then saline IT 112.7 ± 19.7 144.1 ± 12.1 129.4 ± 27.4
SEQUENCE 4    
Saline IT 110.8 ± 9.3 111.2 ± 10.2 129.4 ± 16.3
Then Saline IT 88.3 ± 18.2 94.9 ± 9.9 143.3 ± 19.4
  1. Data represents mean ± SEM
  2. CPG35348 is a selective GABAB receptor antagonist
  3. NBI neonatal bladder inflammation—pretreatment as defined in section “Neonatal bladder inflammation (NBI)” of text; ABI adult bladder inflammation—pretreatment as defined in section “Adult bladder inflammation (ABI)” of text; mcg microgram, ng nanogram
  4. *Statistically significant change (p < 0.05, paired t-test) from previous measure. N = 8–9/group
  5. #Statistically significant difference from Saline-IT Baclofen treated rats in same Pretreatment category (p < 0.05, unpaired t-test)